Carglumic Acid
Carglumic Acid is an orphan drug approved by the U.S. FDA in 2010 for treating hyperammonemia caused by N-acetylglutamate synthase deficiency. It serves as a replacement activator for carbamoyl phosphate synthetase 1, facilitating ammonia detoxification via the urea cycle, and is utilized in both clinical management and related biochemical research.
Product Specifications
CAS Number
1188-38-1
Product Name Alternative
Carbamino-L-glutamic acid, Carbamoyl-phosphate synthase, Carbamylglutamic acid, Carbaglu, Carglumic Acid, N-Carbamylglutamate, N-Carbamyl-L-glutamic acid, inhibit, Inhibitor, Ureidoglutaric acid
Field of Research
Pharmacology & Drug Discovery
Purity
99.54% (May vary between batches)
Solubility
DMSO:45 mg/mL (236.66 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (10.52 mM)
Smiles
[C@@H] (CCC (O) =O) (NC (N) =O) C (O) =O
Molecular Formula
C6H10N2O5
Molecular Weight
190.15
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15336828 1 Vial
Lentiviral human POTEA shRNA (UAS) - Lentiviral human POTEA shRNA (UAS, GFP) (100)
Sign In for Pricing
View Details 
